WallStSmart

Rio Tinto ADR (RIO)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Rio Tinto ADR generates 111692% more annual revenue ($61.79B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 19.6%. RIO trades at a lower P/E of 12.7x. RIO earns a higher WallStSmart Score of 64/100 (C+).

RIO

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 9.0Value: 6.0Quality: 5.5
Piotroski: 1/9Altman Z: 2.03

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.5Value: 5.3Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RIOUndervalued (+29.3%)

Margin of Safety

+29.3%

Fair Value

$138.83

Current Price

$101.10

$37.73 discount

UndervaluedFair: $138.83Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RIO6 strengths · Avg: 8.5/10
Return on EquityProfitability
34.1%10/10

Every $100 of equity generates 34 in profit

Market CapQuality
$158.04B9/10

Large-cap with strong market position

P/E RatioValuation
12.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
28.1%8/10

Strong operational efficiency at 28.1%

Revenue GrowthGrowth
15.5%8/10

15.5% revenue growth

VMET6 strengths · Avg: 9.5/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

RIO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
5.692/10

Expensive relative to growth rate

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
28.7x4/10

Moderate valuation

Market CapQuality
$933.87M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : RIO

The strongest argument for RIO centers on Return on Equity, Market Cap, P/E Ratio. Profitability is solid with margins at 19.6% and operating margin at 28.1%. Revenue growth of 15.5% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : RIO

The primary concerns for RIO are Piotroski F-Score, PEG Ratio.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 594.0% — sustainability is the question.

RIO generates stronger free cash flow (3.2B), providing more financial flexibility.

Monitor OTHER INDUSTRIAL METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RIO scores higher overall (64/100 vs 60/100), backed by strong 19.6% margins and 15.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Rio Tinto ADR

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

Rio Tinto Group is dedicated to the exploration, extraction and processing of mineral resources worldwide. The company is headquartered in London, the United Kingdom.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?